A primary goal in transplantation medicine is the induction of a tolerogenic environment for
prevention of transplant rejection without the need for long-term pharmacological …

Regulatory T cell (Treg) therapy using recipient-derived Tregs expanded ex vivo is currently
being investigated clinically by us and others as a means of reducing allograft rejection …

Solid organ transplantation is the treatment of choice for various end-stage diseases, but
requires the continuous need for immunosuppression to prevent allograft rejection. This …

Adoptive immunotherapy with regulatory T cells (Tregs) is a promising treatment for allograft
rejection and graft-versus-host disease (GVHD). Emerging data indicate that, compared with …

Cell therapy with autologous donor-specific regulatory T cells (Tregs) is a promising strategy
to minimize immunosuppression in transplant recipients. Chimeric antigen receptor (CAR) …

CD4+ CD25 high FOXP3+ regulatory T cells (Tregs) are involved in graft-specific tolerance
after solid organ transplantation. However, adoptive transfer of polyspecific Tregs alone is …

Clinical trials of Treg therapy in transplantation are currently entering phases IIa and IIb, with
the majority of these employing polyclonal Treg populations that harbor a broad specificity …

Cellular therapies with polyclonal regulatory T-cells (Tregs) in transplantation and
autoimmune diseases have been carried out in both animal models and clinical trials …

Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expanded ex vivo is a
promising therapeutic approach which is currently being investigated clinically as a means …

Introduction Cell therapy with regulatory T cells (Tregs) in solid organ transplantation is a
promising approach for the prevention of graft rejection and induction of immunologic …